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Abstract
Background: In principle, risk-stratification as a routine part of the NHS Breast Screening Programme (NHSBSP)
should produce a better balance of benefits and harms. The main benefit is the offer of NICE-approved more
frequent screening and/ or chemoprevention for women who are at increased risk, but are unaware of this. We
have developed BC-Predict, to be offered to women when invited to NHSBSP which collects information on risk
factors (self-reported information on family history and hormone-related factors via questionnaire; mammographic
density; and in a sub-sample, Single Nucleotide Polymorphisms). BC-Predict produces risk feedback letters, inviting
women at high risk (≥8% 10-year) or moderate risk (≥5 to < 8% 10-year) to have discussion of prevention and early
detection options at Family History, Risk and Prevention Clinics. Despite the promise of systems such as BC-Predict,
there are still too many uncertainties for a fully-powered definitive trial to be appropriate or ethical. The present
research aims to identify these key uncertainties regarding the feasibility of integrating BC-Predict into the NHSBSP.
Key objectives of the present research are to quantify important potential benefits and harms, and identify key
drivers of the relative cost-effectiveness of embedding BC-Predict into NHSBSP.
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Methods: A non-randomised fully counterbalanced study design will be used, to include approximately equal
numbers of women offered NHSBSP (n = 18,700) and BC-Predict (n = 18,700) from selected screening sites (n = 7). In
the initial 8-month time period, women eligible for NHSBSP will be offered BC-Predict in four screening sites. Three
screening sites will offer women usual NHSBSP. In the following 8-months the study sites offering usual NHSBSP
switch to BC-Predict and vice versa. Key potential benefits including uptake of risk consultations, chemoprevention
and additional screening will be obtained for both groups. Key potential harms such as increased anxiety will be
obtained via self-report questionnaires, with embedded qualitative process analysis. A decision-analytic model-
based cost-effectiveness analysis will identify the key uncertainties underpinning the relative cost-effectiveness of
embedding BC-Predict into NHSBSP.
Discussion: We will assess the feasibility of integrating BC-Predict into the NHSBSP, and identify the main
uncertainties for a definitive evaluation of the clinical and cost-effectiveness of BC-Predict.
Trial registration: Retrospectively registered with clinicaltrials.gov (NCT04359420).
Keywords: Screening, Breast cancer, Risk stratification, High risk, Psychological impact, Early detection,
Mammographic density, Chemoprevention, Tyrer-Cuzick, Anxiety
Background
Breast cancer is the most common cancer in the UK and
a leading cause of death in women [1]. Each year, ap-
proximately 55,000 women are diagnosed with breast
cancer, of whom approximately 11,400 will die from the
disease [1]. Although deaths from breast cancer have
been decreasing in many Western countries, the inci-
dence of breast cancer is continuing to increase [2–4].
To identify breast cancer at an earlier and more treatable
stage, nearly two million women are screened in the Na-
tional Health Service Breast Screening Programme
(NHSBSP) in England every year [5]. The NHSBSP cur-
rently invites women aged 50 to70 years (though some
breast screening units are trialling screening from ages
47 to 73 years) for three-yearly mammograms. The
NHSBSP also undertakes screening of very high-risk
women with high-penetrance mutations in genes such as
BRCA1, BRCA2 and TP53. These women are offered an-
nual Magnetic Resonance Imaging screening between
ages 30 to 50 years and annual mammography between
40 to 70 years.
In 2013, the National Institute for Health and Care Ex-
cellence (NICE) recommended that women at high risk
of breast cancer who are not high penetrance gene car-
riers (lifetime risk ≥30%, 10-year risk ≥8%), should be of-
fered annual breast screening between the ages of 40 to
59 years; and those at moderate risk (lifetime risk 17–
29%, 10-year risk 3–7.9% aged 40 years), should be of-
fered annual mammography from 40 to 49 years [6], but
considered for annual screening aged 50 to 59 years.
NICE guidance also recommends that women at high
risk of breast cancer are offered chemoprevention with
tamoxifen, anastrozole or raloxifene (considered in mod-
erate risk) and advice on weight control and physical ac-
tivity [6]. So far, it is estimated that only about 1 in 6
women who are at high-risk as defined by NICE (≥8%
ten-year risk of breast cancer) have been actively identi-
fied by attending Family History, Risk and Prevention
(FHRP) Clinics [7, 8].
Risk stratification in the NHSBSP could identify many
of the 5 in 6 women who are at high-risk but are not
aware of this, as well as a larger number of women at
moderate risk. It is possible to accurately estimate a
woman’s individual risk of developing breast cancer
through information on breast density derived from
mammography and self-report questions assessing family
history and factors affecting hormone levels, e.g. using
the Tyrer-Cuzick algorithm [9]. A previous study (PRO-
CAS) provided 10-year risk estimates to over 54,000
women in the NHSBSP in Manchester, England [10].
This study was the first time that personalised breast
cancer risk estimates were calculated for large numbers
of women from the general breast screening population.
The PROCAS study found that at least 3% of women are
high risk (≥8% 10-year risk) when all risk factors includ-
ing mammographic density are assessed and a further
10% are at moderate risk (5–7.9% 10-year risk) [7, 8].
Given that only 0.5% of the population have identified
themselves as high risk, this means that there are ap-
proximately an additional 450,000 women in England
(aged 30 to 70 years) at high risk that NICE guidance in-
dicates should be offered chemoprevention and annual
mammography.
The introduction of risk stratification in the NHSBSP
could allow the potential benefits of more frequent
screening and/ or chemoprevention to be realised on a
population basis, and potentially allow women at lower
risk to have less frequent screening recommended. In
principle, a risk-stratified NHSBSP should result in a
better balance of benefits, harms and NHS costs and
there is some emerging early evidence to support this
premise [11]. The benefits might be fewer breast cancers
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due to chemoprevention, and reduced breast cancer
mortality arising from NHSBSP detecting more breast
cancers at an earlier and more treatable stage. There
might also be grounds for reducing screening for women
at lower risk, who would be less likely to develop high
grade tumours [12]. Reducing screening in women at
lower risk would produce fewer harms of screening in
this group, such as fewer false positive test results in
lower risk women [13].
The consequences of introducing risk stratified screen-
ing in the NHSBSP are unclear. In the PROCAS study,
communication of risk estimates happened 3 to 5 years
after women provided their questionnaire data and con-
sent [10], so that study provides limited information
about the consequences of receiving risk estimates: the
main purpose of that study was to validate risk predic-
tion algorithms rather than as a new screening service
model [8]. It is likely that, if aware of their risks, a
sizeable proportion of women at high/moderate-risk
would opt for chemoprevention with anastrozole/raloxi-
fene/tamoxifen [7, 8, 10, 14, 15], as well as extra mam-
mography in high-risk women [8]. The overall net effect
of chemoprevention and additional screening is likely to
be beneficial from a reduction in breast cancer incidence
and mortality. By contrast, there are also several possible
harms that could be brought about by the receipt of risk
estimates. Communicating personal risk information to
women could induce undue anxiety and worry. Al-
though the best available evidence suggests that this is
unlikely, this evidence has limitations such as a long
time-lag between women agreeing to risk assessment
and receiving risk results [16].
In addition, the mere offer of risk stratified screening
may have potential adverse effects. It is possible that by
offering risk stratified screening as part of the NHSBSP,
women are put off from attending screening and thereby
receiving its benefits. Evidence from PROCAS [10] sug-
gests this is unlikely. Furthermore, as with all screening
programmes within the NHS it is important that pa-
tients are provided with the necessary information in
order to possess the knowledge to make an informed
personal decision about whether to attend screening,
and any treatment options that follow from screening
[17]. There is currently no clear evidence to indicate
whether risk-stratified screening could result in more in-
formed decisions or not [18].
A final important group of possible drawbacks of
implementing risk stratification are the potential costs,
both personal and financial, to implementing the com-
munication of risk information on such a scale, includ-
ing increased NHS staff workload and additional
healthcare resources. Evidence is therefore required
about the key drivers of the relative cost-effectiveness of
communicating breast cancer risk estimates compared
with current NHSBSP practice, understanding the key
uncertainties in the current evidence base and potential
value of future research [19]. Overall, it is imperative in
order to highlight whether risk stratified screening will
induce harms and if so, how they can be mitigated so as
not to outweigh benefits, and allow more effective use of
healthcare resources.
We have developed an automated system (BC-Predict)
for offering an assessment of breast cancer risk to
women when they receive their NHSBSP invitation, and
generating letters to feedback this risk to women and
relevant healthcare professionals. A development phase
involved working with healthcare professionals that en-
sured that the care pathways were workable, and that in-
formatics procedures functioned as intended. The
patient information materials were co-produced with
women who would be eligible for BC-Predict to promote
good understanding and informed choices, and also
minimise harms such as unnecessary worry.
In BC-Predict, risk estimation can be offered in real-
time to women invited for breast screening via an online
web system to allow consent and self-report measures to
be provided. Risk assessment is based on self-report
questions and breast density estimates automatically de-
rived from mammography, and can also incorporate in-
formation from currently known breast cancer Single
Nucleotide Polymorphisms (SNPs), derived from DNA
contained in saliva samples. Women who receive a clear
mammogram result are then sent a letter providing their
10-year breast cancer risk within 6 to 8 weeks after their
mammogram. Thus all women will know their risks.
Those women at moderate (> 5% but < 8% 10-year risk)
or high (≥8% 10-year) risk are encouraged to attend a
consultation at a FHRP Clinic, to discuss the offer of
more frequent screening and chemoprevention.
Although developmental work has shown BC-Predict
to function as intended, it would not be appropriate to
implement a system such as BC-Predict outside of a re-
search setting, given the uncertainties around potential
benefits, possible harms and cost effectiveness [20]. It
would not even be proportionate or ethical to conduct
the required large-scale definitive evaluation of clinical
and cost-effectiveness, as this which would require the
participation of hundreds of thousands of women to
have sufficient power to detect its effect on breast cancer
incidence and stage. Therefore, in line with the MRC
Framework for Developing and Evaluating Complex In-
terventions [21], the present research has the goal of
identifying and resolving key uncertainties regarding the
feasibility of integrating BC-Predict into the NHSBSP
and assessing the feasibility of a definitive study to assess
whether the intervention translates into measurable ef-
fects on breast cancer incidence and stage, and is a cost-
effective use of NHS resources. The present research will
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therefore quantify key drivers of the relative cost-
effectiveness of communicating breast cancer risk esti-
mates compared with current NHSBSP practice, under-
standing the key uncertainties in the current evidence
base and potential value of future research.
A particular concern during the development phase
was that that women from low socioeconomic and mi-
nority ethnic backgrounds are less likely to attend for
screening [22–24]. Commonly cited reasons include lan-
guage barriers, cultural incongruences and lack of un-
derstanding and knowledge about screening [22, 25, 26].
It is not presently known whether the introduction of
risk-stratified screening would exacerbate these issues
further or lead to increased non-attendance. In develop-
ing BC-Predict, interviews with a cohort of British-
Pakistani women from low socioeconomic backgrounds
found that views toward risk-stratified screening are
favourable. However, as with the present screening
programme language barriers could still prevent access
and reduce women’s ability to make informed decisions
[27]. Given this, in the present study we will assess
whether women from low socioeconomic status back-
grounds are less likely to take up the offer of risk-
stratified screening.
The overall aim of the present research will be to es-
tablish whether providing women eligible for NHSBSP
with personalised breast cancer risk (BC-Predict) estima-
tion is feasible, by (a) measuring important potential
harms and benefits of BC-Predict, (b) identifying the key
drivers of the relative cost-effectiveness of embedding
BC-Predict into the NHSBSP, and (c) attempting to
understand the key issues affecting implementation of
BC-Predict as part of the NHSBSP. This overall aim will
be met by evaluating the BC-Predict system in a 16-
month study running within the Greater Manchester,
East Cheshire and East Lancashire NHS breast screening
programmes, with the following three overarching
objectives:
Quantifying important potential benefits, particularly
(a) Uptake of BC-Predict amongst women offered it
(b) Uptake of risk consultation (for those eligible)
(c) Uptake of chemoprevention (for those offered it)
(d) Uptake of additional mammography (for those
offered it)
Quantifying important potential harms, particularly
(a) Lower uptake of NHSBSP amongst women offered
BC-Predict
(b) Increased worry about breast cancer
(c) Increased general state anxiety
(d) Less informed choices regarding screening uptake
Quantifying indicative estimates of the NHS costs and
patient consequences, including
(a) Effects on health status and healthcare costs
(b) Key drivers of the relative cost-effectiveness of em-
bedding BC-Predict into the NHSBSP
(c) Extent of uncertainty in the current evidence-based
(d) The potential value of future research.
Methods/design
Study design
A non-randomised fully counterbalanced study design
will be used, to include equal numbers of participants
from all sites who will be offered NHSBSP and BC-
Predict. Specifically, in the initial 8-month time period,
four screening sites will offer women eligible for breast
screening BC-Predict. Three screening sites will offer
women usual care NHSBSP. In the following 8-month
time period the study sites switch to offer the other
intervention (NHSBSP rather than BC-Predict; and vice
versa). This ‘counter-balanced’ design will allow esti-
mates of effect to be obtained from both within-sample
and between-sample analyses.
Setting
Women will be recruited from seven sites within three
NHS Breast screening programmes: three sites within
the Greater Manchester programme (Withington Com-
munity Hospital, Oldham lntegrated Care Centre and
the Trafford mobile screening van only), and two sites
each based in the East Cheshire (Macclesfield District
General Hospital and Stockport mobile breast screening
van locations) and East Lancashire (Burnley General
Hospital and East Lancashire mobile breast screening
van locations) programmes. Women invited to screening
in East Cheshire and Withington/Trafford in the first 8
months of the study will be offered BC-Predict and
women in East Lancashire and Oldham offered screen-
ing as usual. After 8 months, BC-Predict will be offered
to women in East Lancashire and Oldham, with women
in Cheshire and Withington/Trafford offered screening
as usual.
Participants
Recruitment is over a 16-month period and sites will
each be open to recruitment to BC-Predict for a period
of 8 months. Two groups of women will be invited to
participate in the study (a) women invited for first time
screening (“prevalent screens”), and (b) women invited
during the screening round within which they reach 60
years (“incident screens” i.e. women aged 57 to 63 years).
Posters advertising the study will be displayed in each of
the participating screening sites to increase awareness of
the study.
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We will include women who are invited for usual care
(NHSBSP) at each site to compare with women offered
BC-Predict; however NHSBSP women will not be con-
sented to the study as controls, as their personal infor-
mation will not be accessed. Instead, core outcome
measures will be obtained in aggregated form. This will
provide a comparison with uptake to these services in
the BC-Predict arm. Posters at study sites will inform
women being offered NHSBSP that they can request
their data is not included in any analysis.
Inclusion criteria are that the participant: (a) is born
biologically female; (b) is invited for first breast screen-
ing appointment (any age); is aged 57 to 63 years (only
at East Cheshire and East Lancashire NHSBSP); and (c)
is able to provide informed consent and complete a risk
assessment questionnaire. Exclusion criteria are that the
participant: (a) is born male; (b) previously had breast
cancer; (c) had bilateral mastectomy; or (d) has previ-
ously participated in the PROCAS study [10].
Procedure
Women being offered BC-Predict will be sent an invita-
tion letter one to two working days after their breast
screening invitation letter is sent. The BC-Predict invita-
tion letter will be sent along with the participant infor-
mation sheet and instructions directing prospective
participants to the online risk assessment platform. Each
invitation letter will include details of the participant’s
“Date of first offered appointment”. This is the first
breast screening appointment date that was offered to
the participant. This date is of relevance because
participants will be able to join the study either before
the date of their first offered appointment or up to six-
weeks after. After this time it will no longer be possible
for them to login to the BC-Predict risk assessment plat-
form. Prospective participants will be directed to tele-
phone the study helpline if they have any questions, or if
they require any further information prior to deciding
whether or not to take part. The timeline from the par-
ticipant perspective is shown in Fig. 1. An overview of
data-flows is shown in Fig. 2.
Once participants have consented to the study online,
they will be directed to the BC-Predict risk assessment
questionnaire. Participants will be able to enter part of
the questionnaire, save and return to it at a later date, as
long as they do this within their six-week recruitment
window. Assessment of the online questionnaire during
the pilot phase estimated that most women would be
able to complete this within 30min. If a prospective par-
ticipant doesn’t have access to the internet, a paper ver-
sion of the questionnaire can be posted out to be
completed along with a paper version of the consent
form. The data recorded on the questionnaire will then
be manually inputted into the online risk assessment
platform by a member of the study team, and the stand-
ard process will be followed from this point.
Once a clear mammogram result has been provided, a
risk feedback letter is generated based on the answers
participants give in their questionnaire and mammo-
graphic breast density (calculated from uploaded raw
data by Volpara systems). The percentage density is
inserted into an online version of Tyrer-Cuzick v8 that
Fig. 1 Timeline of Psychological-Impact study integrated with BC-Predict and NHSBSP
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includes an algorithm to adjust density for age BMI and
menopausal status in into an odds ratio known as dens-
ity residual [14]. The risk feedback letter will inform
women that they are at “high” (≥8% 10-year risk), “mod-
erate” (≥5% but < 8% 10-year risk), “average” (≥ 2% but
< 5% 10-year risk), or “below average” risk (< 2% 10-year
risk). Each letter will explain how the risk estimates were
derived, and the implications of these. Each group of
women will receive this letter in the post, along with a
leaflet providing additional detail on breast cancer risk
factors, signs and symptoms of breast cancer and how
risk might be managed. Those women who complete the
BC-Predict risk assessment questionnaire over the tele-
phone will also be sent copies of this questionnaire so
that they can check for data entry errors and the elec-
tronic consent form for participant’s records.
All BC-Predict participants will have been invited for
breast screening but a proportion may choose not to at-
tend their breast screening appointment; attendance at
breast screening mammogram is not a compulsory part
of the study. The Participant Information Sheet explains
that participants’ mammographic breast density will be
included in their risk assessment, providing they attend
their mammogram within 6-weeks of their first offered
appointment. It is also explained that including mammo-
graphic density increases accuracy of the risk assess-
ment. Any participant who declines a mammogram or
has a mammogram after this time will not have this data
included in their risk assessment, which is explained in
their risk feedback letter.
To assess self-reported harms and benefits, and to in-
form an economic analysis, a randomly selected sub-
sample of n = 2108 women (n = 1054 each from usual
care NHSBSP and BC-Predict) will be asked to complete
questionnaires assessing psychological benefits and
harms of BC-Predict at baseline, 3-months and 6-
months. For women in both groups, the request to
complete the questionnaire will be sent shortly after
their mammography invitation but before their first of-
fered mammogram appointment, asking for their help in
evaluating a new approach to providing NHS breast
screening. They will be given instructions to complete
an online consent form and questionnaire using their
unique study identification number on SmartSurvey
(https://www.smartsurvey.co.uk/). The same women will
be asked to complete the questionnaire three and 6
months after their first offered mammogram appoint-
ment. Women in both experimental groups will only re-
ceive follow-up questionnaires once they receive a clear
mammogram result.
The risk assessment and feedback will take account of
each patients’ journey through the NHSBSP. The study
team will periodically check screening outcomes for par-
ticipants. There are a number of initial screening out-
comes: (a) clear mammogram and woman will be invited
for routine breast screening in three-years (routine re-
call); (b) mammogram taken is technically inadequate so
repeat mammogram is required (technical recall); (c):
suspicious mammogram and further assessment re-
quired (recall for assessment). For all scenarios the GP
will be informed of the participant’s involvement in the
study and provided with their risk feedback.
Participants who are confirmed as having a routine re-
call screening outcome will receive their risk feedback
after this, approximately 6 weeks after their mammo-
gram. Participants who are invited for a technical recall/
Fig. 2 Study Participant Data Flow Diagram
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recall for assessment appointment, and attend this ap-
pointment within 6 months of their first scheduled tech-
nical recall/recall for assessment appointment, and who
are subsequently confirmed as not having breast cancer
will receive a risk feedback letter following confirmation
of an absence of breast cancer. Participants who are in-
vited for a technical recall or recall for assessment ap-
pointment but do not attend within 6 months of the
first scheduled technical recall/recall for assessment ap-
pointment (i.e. those for whom there is no screening
outcome within 6 months of initial screening outcome)
will receive their risk feedback 6 months after joining
BC-Predict.
Participants who do not attend a breast screening ap-
pointment within six-weeks of their first offered breast
screening appointment will receive their risk feedback
after this six-week period (i.e. 7 to 8 weeks since their
first offered breast screening appointment).
Participants who are diagnosed with breast cancer will
not receive a standard risk feedback letter. Participants
will be sent a letter 1 year after diagnosis which will offer
them feedback from the study. If they opt to receive this,
they will be sent a personalised letter explaining their
breast cancer risk factors.
Measures
Two main types of measures will be used: core outcome
measures and self-reported measures.
Core outcomes
The following nine core outcomes will be compared at 6-
months post completion of recruitment for those offered
BC-Predict and those offered usual care (NHSBSP):
1. Screening attendance at first offered screening
episode.
2. Screening attendance within 180 days of episode
opening.
3. Number of technical recalls.
4. Number of recalls for assessment.
5. Number of routine recalls.
6. Number of breast cancer diagnoses (and type/
grade).
7. Subsequent consultation in FHRP clinics (and mode:
telephone or face-to-face).
8. Subsequent enrolment for more frequent screening.
9. Subsequent prescription of chemoprevention. Data
will be collected on each of the following aspects of this:
(a) participant agrees/disagrees in clinic to take chemo-
prevention, (b) chemoprevention not appropriate, (c)
chemoprevention appropriate but prescription not filled,
(d) chemoprevention appropriate and prescription filled.
Data for the nine core outcomes will be collected for
each consented BC-Predict participant by the research
staff for the 6 months following participants’
mammography appointment. For these participants, infor-
mation will be available directly from NHSBSP and FHRP
clinic records. For those in the usual care arm of the study,
anonymised data will be provided by NHSBSP and FHRP
services, to provide overall numbers for each of the core
outcomes. We will prospectively record any refinements
to procedures, to allow examination of how these impact
on uptake of services.
We will also assess uptake of BC-Predict, and examine
variation by study site. Where changes to recruitment
procedures are made, we will keep notes of this, and
examine the effects of these changes on uptake of BC-
Predict, to inform how risk stratified screening should
be rolled out. We will also examine variations in uptake
of services by Index of Multiple Deprivation deciles de-
rived from postcode of women [28] invited for NHSBSP,
to assess any potential exacerbation of health inequalities
brought about by BC-Predict.
Self-reported outcomes
The self-reported measures of potential harms and bene-
fits of BC-Predict to be completed by a sub-sample of
participants are shown in Table 1.
Analysis plan and power calculations
Core outcomes
In total, approximately n = 18,700 women will be offered
BC-Predict and n = 18,700 will be offered usual care
NHSBSP over the total 16-month period. Based on the
recruitment rate in PROCAS, n = 18,700 women being
offered BC-Predict should result in 8000 women taking
it up. The attendance rate to usual NHSBSP in Greater
Manchester is 69% [5, 10].
Core outcomes will be compared for cohorts of
women who are invited to BC-Predict and those who are
invited to usual care (NHSBSP). Thus we will have in ex-
cess of 8000 participants in BC-Predict and NHSBSP
groups for both comparisons: (a) within-site and (b) be-
tween sites over the same time period. The primary out-
comes are binary. Logistic regression will be the primary
statistical analysis method. We shall assess heterogeneity
effects using interaction tests in the logistic regression,
to examine differences in outcomes by time or location
or screening type (prevalent v incident). Even in the
presence of geographic or temporal heterogeneity of the
effect, or of carryover effects continuing beyond the
crossover period, we will still have sufficient data for a
valid and fully powered comparison.
For core outcomes 1 and 2, we are interested in
equivalence, in that we anticipate that invitation to BC-
Predict will not substantially affect screening attendance.
With 18,700 women in each group we will have in ex-
cess of 90% power to establish equivalence, defined as a
95%CI on the difference which does not exceed ±5% on
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the attendance rate at first offered appointment, if the
latter is around 50% [37]. Similarly, we will have more
than 90% power for the same comparison for eventual
attendance within 180 days if the latter is around 70%.
Arguably, the most difficult to collect core outcome is
9, the proportion taking up chemoprevention. On the
basis of PROCAS results we would anticipate that 1169
of the 8000 who consent to BC-Predict would have suffi-
cient risk to be considered for chemoprevention and that
10% of these would take it up [8, 38, 39]. Thus 117 of
the 8000 women (1.5%) receiving the intervention might
be expected to be prescribed chemoprevention. It is an-
ticipated that very few in the 18,700 sent the standard
screening invitation would be prescribed chemopreven-
tion, but even if as many as 0.9% did so, we would have
90% power to detect this as significant at 5% level with
two-sided testing, and 80% power if 10% took up chemo-
prevention. The Greater Manchester Medicines Manage-
ment group has agreed a shared care protocol stating
that the initial prescription of tamoxifen and anastrozole
should be made by a FHRP specialist. As such data from
even those in the control arm should be available from
prescriptions made in the FHRP clinics.
Self-reported outcomes
Analyses will focus on comparisons between the re-
sponses of the BC-Predict and NHSBSP groups at 6
months follow up, controlling for baseline responses and
baseline patient characteristics. We will use ANCOVA,
first with baseline responses to the same questionnaires
as covariates, secondly treating both baseline and 6-
month responses as related endpoints, using hierarchical
linear models. Out of the available self-reported out-
comes, we have selected the primary outcome to be anx-
iety (State Trait Anxiety Inventory) at 6-months, but we
will also examine effects on all measures included in
Table 1, as well as effects at 3 months. We will use the
variables concerning knowledge, and attitudes to screen-
ing, as well as screening attendance, to assess the extent
to which decisions to attend screening are informed, in
line with a standard approach to assessing this [17]. The
measures of health status (EQ. 5D-5 level) and capability
(ICECAP-A) will be converted to preference weights
using published algorithms [40] and population tariffs
[41], as appropriate.
In addition to providing information about potential
harms of BC-Predict, secondary analyses will examine
whether women who are randomised to receive ques-
tionnaires differ in terms of uptake of screening or BC-
Predict. This will inform about the likelihood of biases
being introduced by comparisons of questionnaire re-
sponses in a possible subsequent definitive trial.
The sample size calculation is based on the six-item
short-form of the state scale of the State Trait Anxiety
Inventory [29], which measures general anxiety currently
experienced on a scale of 20 to 80. Previous research in
England with women invited to breast cancer screening
found a mean state anxiety score of 37 [42]. A score of
49 has been found in patients with a diagnosis of anxiety
disorder [43].
Assuming a two-tailed independent samples t-test,
then n = 1054 (n = 527 women per experimental group)
will be required to have 90% power (with α = 0.05) to de-
tect a small standardised difference of d = 0.2. This
equates to a difference between adjacent response cat-
egories (e.g. “not at all” and “somewhat”) on 2.5 of the
20 items on the full form of the scale. We anticipate that
asking 1054 women per group will result in responses
from n = 527 women per group being obtained at both
baseline and 6 months, assuming a 70% response rate on
both rounds.
Economic analysis
An early economic analysis [44] will aim to identify the in-
dicative estimates of the incremental costs and conse-
quences and key drivers of the cost-effectiveness of a risk-
stratified NHSBSP compared with the usual NHSBSP. A
decision-analytic model-based cost-effectiveness analysis
Table 1 Self-reported measures to be assessed, at each of the three timepoints.
Baseline 3 months 6 months
State Anxiety [29] State Anxiety [29] State Anxiety [29]
Cancer Worry [30] Cancer Worry [30] Cancer Worry [30]
Risk perceptions [31] Risk perceptions [31] Risk perceptions [31]
Attitudes to screening [32] Attitudes to screening [32]
Knowledge [33] Knowledge [33]
Intention (future screening) [32] Intention (future screening) [32] Intention (future screening) [32]
Health status (EQ-5D5L) [34] Health status (EQ-5D5L) [34] Health status (EQ-5D5L) [34]
Capability [35] Capability [35] Capability [35]
Satisfaction with information [36] Satisfaction with information [36]
*Informed choices regarding screening will be estimated from attitudes to screening at baseline, knowledge and screening attendance, using a standard approach [17]
**Women invited to BC-Predict will receive the above. Women invited to NHS-BSP will receive the above minus the satisfaction with information questionnaire
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will capture the incremental NHS costs and consequences
for a cohort of women eligible for NHSBSP in the UK
over a life-time horizon. A decision-analytic model (a
decision-tree combined with a published model) [11] will
be structured to represent the care pathways of current
NHSBSP practice (no risk feedback) and the proposed
BC-Predict intervention in a sample of women eligible for
the NHSBSP. The cost of the risk-stratified NHSBSP will
be identified using a micro-costing study [45] and take ac-
count of the cost of the addition of SNPs to the risk esti-
mation algorithm. The decision-tree will recognise the
uptake of appropriate healthcare services (General Prac-
tice contact; FHRP Clinic referral and proportion of
women starting chemopreventive medication e.g. anastro-
zole/tamoxifen/raloxifene). A published model [9] will be
used to understand the lifetime impact on NHS costs and
patient consequences of using different screening intervals
based on risk-prediction, or usual NHSBSP. Using an eco-
nomic model allows data assimilation from various
sources (BC-Predict and systematic reviews; structured ex-
pert elicitation methods [46]) in a structured framework
[47]. The model-base case analysis will focus on changes
in health status (using EQ-5D-5 L) but explore the impact
on capability (ICECAP-A) in a scenario analysis. These
data will be obtained from the self-reported outcomes
(health status (EQ-5D5L) [34]; capability (ICECAP-A)
[35]) collected in the prospective study (see Table 1) and
supplemented with published data to allow estimation of
the impact on a life-time horizon. The EQ-5D5L [34] and
ICECAP-A [35] have published preference weights that
will allow calculation of quality adjusted life years for
health and capability with and without the intervention.
Parameter uncertainty in the decision-tree component of
the model will be quantified using probabilistic sensitivity
analysis for the base case analysis and scenario (capability)
analysis. These two outcomes (health and capability) will
then be used in two distinct value of information analyses
(Expected Value of Perfect Information (EVPI) and ex-
pected value of partial perfect information (EVPPI)). The
EVPI represents the maximum amount that should be
spent on future research to gain perfect information to
eliminate the possibility of a wrong (funding) decision.
Further steps are then necessary to understand key pa-
rameters driving the uncertainty. This involves estimating
the EVPPI that tells a decision maker which parameters
are contributing to the uncertainty in the model and help
to guide what type of additional evidence is most valuable.
Three sub-studies
The present research also includes sub-studies. Although
integral to the overall research, they are described here,
to facilitate clear presentation of their aims and
methods.
Sub-study one: incorporation of SNP information into BC-
predict risk estimates
Objectives
To determine uptake and acceptability of a DNA based
risk estimate as part of routine NHSBSP appointments,
and to quantify the higher proportions of women at
high/moderate and lower risk obtained by adding SNP
information.
Background
A subset of women will have the option to provide a
sample of saliva from which DNA can be extracted.
DNA will be extracted with standard techniques and
currently known breast cancer SNPs associated with
breast cancer typed. The results of this testing will be in-
corporated into the BC-Predict risk algorithm. Adding a
genetic SNP score from a saliva sample to other risk fac-
tors not only potentially increases the accuracy of risk
estimation, but also increases the discrimination of risk
estimation, so that more women are identified as being
at higher or lower risk, and fewer identified as being at
population-average risk. It thereby increases the propor-
tion of women identified at high-risk who can benefit
from being offered NICE approved additional screening
and drug prevention from 4 to 6%.
Methods
In total, it is expected that 1000 women will provide a
DNA sample and receive a personalised breast cancer
risk estimate incorporating their Polygenic Risk Score.
All women invited for screening at Withington Commu-
nity Hospital and Oldham Integrated Care Centre will
be potentially eligible for the SNP sub-study, however,
this will only be offered to women on a pragmatic basis
depending on whether a member of staff is on site to as-
sist with taking consent. A separate paper consent form
will be completed by the participant in addition to the
online consent form for the main study. Women giving
their consent will be provided with an Oragene kit to
place their salivary sample. They will be guided on site
by a member of staff as to how to complete the sample.
Methods: data analysis
The proportion of women in the 1000 providing saliva
DNA who are classified as NICE actionable high and
moderate risk as well as below average risk will be com-
pared to their classification without a SNP Polygenic
Risk Score. Chi square statistics will compare the differ-
ence between risk categories with and without the
addition of the SNP Polygenic Risk Score. These data
will also be used in the proposed economic analysis.
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Sub-study two: understanding acceptability and
implementation of BC-predict
Objectives
The main objectives are to explore service users’ views
on acceptability of BC-Predict (interviews) and to assess
the perceived impact of BC-Predict on the NHSBSP,
FHRP Clinics and General Practice (focus groups).
Background
In addition to the quantitative measures of impact of
BC-Predict, we will also carry out qualitative work as
part of a process evaluation to understand the key issues
behind successful implementation of the BC-Predict sys-
tem [48]. The qualitative work will comprise one-to-one
interviews with NHSBSP service users to explore accept-
ability of BC-Predict amongst women at varying levels of
risk, where there is currently a dearth of evidence [49].
It will also employ focus groups with healthcare profes-
sionals to investigate the implementation, delivery and
impact of BC-Predict on the current NHSBSP. This
qualitative work will give insight into capacity issues, in-
dication of the training and support required to deliver
BC-Predict on a larger scale, as well as communication
challenges and pathways for both service users and
healthcare professionals. This will enable us to build an
evidence base to inform practice and policy should BC-
Predict be rolled out to the wider NHSBSP.
Methods
Patient interviews: design, sample, recruitment and
data collection A purposive sample of below average,
average, moderate and high-risk women who had re-
ceived BC-Predict will be invited to participate in a
semi-structured interview. Below average and average
risk women will be invited for interview 1 month after
receiving their risk feedback letter. Moderate-risk and
high-risk women will be invited for interview 6months
after receiving their risk feedback letter. This gives
women in the moderate and high-risk groups the chance
to explore extra screening options or medications prior
to the interview. The BC-Predict online platform allows
easy identification of women in each risk group in each
location. We will aim to recruit up to 40 women to these
interviews (up to 10 women per group) with variation in
which study sites to which women were invited. In
addition, questionnaire responses will guide sampling to
allow variation in uptake of chemoprevention.
Data will be collected by semi-structured interview ei-
ther face-to-face or over the phone, audio recorded and
transcribed verbatim. The decision to stop recruitment
will be based on whether the data collected is sufficient
to answer the research questions and aims [50]. There-
fore the depth of the data will be used as an indicator to
cease recruitment. The decision to end recruitment will
also be based on the active exploration of negative cases,
as well as when there appears to be no new content be-
ing discussed in the final interviews of each risk group.
All interviews will cover core issues including acceptabil-
ity of BC-Predict and lifestyle modifications. Other is-
sues will be covered are those that are most relevant to
the risk estimate communicated, e.g. uptake of chemo-
prevention (e.g. GP advice) in higher risk women, and
reassurance in below-average risk women. We will be
sensitive to considering naturally occurring variation,
e.g. women recruited differently due to SNP collection
or across different study sites, or from diverse ethnic
backgrounds.
Healthcare professional focus groups: design, sample,
recruitment and data collection General Practice,
Radiology and FHRP Clinic staff will be invited to par-
ticipate in focus groups 2 months after BC-Predict has
stopped being provided in each location. The groups will
examine how well prepared they and associated staff
were for implementing BC-Predict, along with views on
acceptability of BC-Predict and how its implementation
could be facilitated when widely implemented. We will
run a multidisciplinary focus group in each location
(total sample = ~ 36). Focus groups will be audio re-
corded and transcribed verbatim. If a participant is un-
able to attend the focus group but would like to take
part, they will be given the option to be interviewed
face-to-face or over the phone.
The analysis of these data will also be used to generate
a list of additional resources required and a quantitative
estimate of the impact on resources such as staff time.
The groups will also aim to estimate the approximate
cost of providing the BC-Predict intervention. These es-
timates will inform the economic analyses.
Methods: data analysis
For both interviews and focus groups, data will be ana-
lysed using a manifest level approach to thematic ana-
lysis as the themes are likely to be predominately
deductive. Thematic analysis seeks and reports the pat-
terns inherent within the data collected. It is a common
qualitative analysis method that results in a rich, com-
plex, yet accessible account of the data [51]. Themes will
be coded at the manifest (or explicit) level [52]. It will
do so taking an essentialist approach, which means that
we aim to report the experiences, meanings and the real-
ity of the participants [53].
Coding will be conducted systematically and itera-
tively. Negative cases will be sought to test the emerging
coding framework. Regular coding meetings will be held
to refine the coding structure. Data will be coded by in-
dependent researchers to check reliability in qualitative
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methods and ensuring that the fit between data and ana-
lysis is maximised. Percentage agreement on presence
will be calculated. Coding will continue until the team
are satisfied that codes and themes adequately describe
and capture the data. Data will be stored and organised
within Nvivo software.
Sub-study three: assessing feasibility of increasing
screening interval for women at low risk
Objectives
To evaluate the impact of providing materials for
women at low risk explaining that less frequent screen-
ing may provide a better balance of benefits and harms
for them.
Background
Women at lower risk of breast cancer are likely to re-
ceive less benefit from the NHSBSP but are more likely
to experience overdiagnosis and treatment for cancers
that will not cause them harm if left untreated. In this
sub-study, we have chosen the risk threshold of 1.5% or
below in newly screened women over 10 years, as this is
the average risk level for a 40-year old woman, who cur-
rently would not be screened for a further 10 years.
(Note that in the rest of the PROCAS study, a threshold
of 2% or below was used to indicate below-average risk
[10], so we use the term “low” to distinguish this distinct
threshold in the present research). PROCAS indicated
that 13.5% of women screened have a 10-year breast
cancer risk of less than 1.5% when assessed by Tyrer-
Cuzick and mammographic density [10]. This group of
women are at a lower risk of developing breast cancer
and the tumours they develop are much more likely to
be early stage and slow-growing [10, 12]. Existing data
suggest that a risk stratified NHSBSP may not only be
potentially cost-effective [11], but also that it may be po-
tentially more cost-effective to delay screening in low-
risk women by optimising the screen interval [54].
Nearly 90% of the population have indicated that
“screening is almost always a good idea” [55] and many
women would feel aggrieved if they felt they were being
denied a service inequitably. Relatedly, attendance at
screening provides reassurance and peace of mind [56],
so a lack of screening may result in increased worry
about breast cancer. However, this view may be partly
due to a lack of general awareness of issues such as over-
diagnosis [57]. Many national screening figures believe
that less frequent screening for women at low risk
may be an important component of risk-stratified
screening. Further, our ongoing developmental work
suggests that this idea is acceptable to many women,
including women who have received a below-average
risk estimates.
Methods: design, sample, recruitment and data collection
In the final 4 months of the 16-month period of imple-
mentation of risk estimation, we will extend the offer of
risk provision to include information about how, for
women at low risk of breast cancer delaying further
NHSBSP for a further period of 5 years may provide a
better balance of benefits and harms for them. This in-
formation will be presented to all women in East Lanca-
shire and Oldham as part of the invitation process, and
repeated for women at low risk (< 1.5% over 10 years) as
part of their risk feedback letter and accompanying leaf-
let. Every woman identified as being at low risk will be
asked to complete the online questionnaire assessing
harms and benefits of BC-Predict at 6 months, in con-
trast to the main BC-Predict study, where only a sub-
sample will be asked to complete this questionnaire.
Methods: data analysis
The primary outcome for this sub-study will be inten-
tions to take up screening in 3 years in women assessed
6 months after being told that they are at low risk and
receive the recommendation to delay attending screen-
ing. Our main focus will be on estimating the proportion
of women intending to take up screening, but we will
also formally compare this proportion with women who
receive provision of “below average risk” breast cancer
risk estimates (< 2%) but no screening recommendations,
recruited over the previous 12months of BC-Predict.
Intention to attend screening is a consistent predictor of
subsequent screening attendance (r = + 0.42 in a system-
atic review that identified k = 19 such tests) [58].
Qualitative process analysis
A qualitative process analysis will be conducted in line
with MRC guidance [48]. A sample of low risk women
(up to n = 12) who had received low risk estimates will
be interviewed 1 month after receiving the feedback let-
ter. They will be sample purposively to provide variation
in the three screening sites (Oldham Integrated Care
Centre, Burnley General Hospital and East Lancashire
mobile breast screening van). Interviews will focus on
the extent to which the possibility of receiving an esti-
mate of low risk was considered before consenting to
risk estimation, the acceptability of the information
communicated and particularly the recommendation to
delay screening, and any deliberations about delaying
screening. Data will be analysed using a manifest, in-
ductive thematic analysis, and will involve comparison of
interviews with those women told they are at below
average risk, but given no particular recommendation.
A decision analytic model-based economic analysis
A decision analytic-model based economic analysis will
be used to understand the potential relative cost-
French et al. BMC Cancer          (2020) 20:570 Page 11 of 14
effectiveness of using a modified screening interval for
women identified to be at low-risk of breast cancer as
part of a stratified-BSP compared with the current
NHSBSP. This analysis will build on an early economic
analysis we previously conducted [11]. The model will
be populated with data from the published literature and
the current study to understand the relative costs and
benefits of the modified screening interval for low-risk
women assuming the perspective of the NHS and the
impact on QALYs over the lifetime horizon for the de-
fined population of women eligible for NHSBSP. Exten-
sive sensitivity analysis will be used to understand the
key drivers of relative cost-effectiveness when imple-
menting a modified screening interval for low-risk
women.
Discussion
The present research aims to provide evidence on the
feasibility of risk-stratified screening, by providing infor-
mation about likely effects, both positive and negative,
and which of these effects are likely to drive cost effect-
iveness. Due to the wish to avoid participant burden,
some additional potential benefits and harms of screen-
ing were not examined, and merit consideration in fu-
ture research.
One key issue that the present research does not cover
relates to the possible benefit that risk estimation may
prompt women to consider changes in their health-
related behaviours to reduce cancer risk. An estimated
20–30% of breast cancer cases are thought to be attrib-
utable to excess weight, weight gain lack of physical ac-
tivity (PA) and high alcohol intakes [59–61]. In general,
communicating personalised risk in the absence of sup-
portive programmes has small effects on increasing
healthy lifestyle behaviours that are not maintained [62,
63]. Nevertheless, studies that have used personalised
risk communication to bring about changes in health-
related behaviours to date have not used additional strat-
egies to optimise behaviour change for which there is
good evidence [63]. Further, even small effects on these
behaviours are achieved by communicating personalised
risk information, then large population reductions in
these unhealthy behaviours should follow.
The BC-Predict feedback materials include informa-
tion on which behaviours are likely to reduce breast can-
cer risk, but the programme does not include any
attempts at promoting health-related behaviour change.
Women at higher breast cancer risk will have a greater
proportional risk reduction through following healthy
lifestyle recommendations [64, 65]. There is evidence
that these women may also be more motivated to ini-
tially engage with evidence-based behaviour change pro-
grammes, maintain engagement, and thereby produce
more behaviour change [66]. By contrast, it is possible
that the provision of low risk results to women my pro-
duce false reassurance. This could result in women at
low risk being less inclined to engage in behaviours
likely to promote health although the wider evidence
suggests that is not likely [67].
The present research will provide key information on
feasibility of implementing risk-stratified screening into
routine breast cancer screening. It complements two
large ongoing trials. The WISDOM trial in the USA [68]
and the MyPeBS trial in several European countries [69]
are designed to show that risk-stratified screening is
non-inferior to routine breast cancer screening, in terms
of the number of late-stage cancers detected. In particu-
lar, the present research does not focus on effectiveness,
but instead will provide information about the likely
harms and benefits of risk-stratified screening, and will
identify what are the key uncertainties that are likely to
inform effectiveness and cost-effectiveness. It also has a
more pragmatic focus than these two large ongoing tri-
als, in considering what are the likely effects on the
healthcare system when implementing risk stratification
as part of routine NHSBSP, including an explicit quanti-
tative and qualitative process analysis of the effects of
this implementation.
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